Harbin Medical University Affiliated Cancer Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lou, Ge
PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

Recruiting
2
83
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
NCT05444374: A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Not yet recruiting
2
48
RoW
Serplulimab, Bevacizumab
Sichuan Cancer Hospital and Research Institute
Cervical Cancer
09/24
12/25
AK104-IIT-024, NCT05824494: Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Not yet recruiting
2
58
NA
Cadonilimab, Nab paclitaxel
Women's Hospital School Of Medicine Zhejiang University, Akeso
Uterine Cervical Neoplasms, Cancer of Cervix, Cervical Cancer, Cervical Neoplasms, Uterine Cervical Cancer, Cancer of the Uterine Cervix
06/26
06/26
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated
1
56
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Platinum-resistant Ovarian Cancer
05/23
05/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lou, Ge
PROFECTA-II, NCT04374630: Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

Recruiting
2
83
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
NCT05444374: A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Not yet recruiting
2
48
RoW
Serplulimab, Bevacizumab
Sichuan Cancer Hospital and Research Institute
Cervical Cancer
09/24
12/25
AK104-IIT-024, NCT05824494: Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Not yet recruiting
2
58
NA
Cadonilimab, Nab paclitaxel
Women's Hospital School Of Medicine Zhejiang University, Akeso
Uterine Cervical Neoplasms, Cancer of Cervix, Cervical Cancer, Cervical Neoplasms, Uterine Cervical Cancer, Cancer of the Uterine Cervix
06/26
06/26
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated
1
56
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Platinum-resistant Ovarian Cancer
05/23
05/23

Download Options